Cargando…
Empagliflozin in acute myocardial infarction: the EMMY trial( )
AIMS: Sodium–glucose co-transporter 2 inhibition reduces the risk of hospitalization for heart failure and for death in patients with symptomatic heart failure. However, trials investigating the effects of this drug class in patients following acute myocardial infarction are lacking. METHODS AND RES...
Autores principales: | von Lewinski, Dirk, Kolesnik, Ewald, Tripolt, Norbert J, Pferschy, Peter N, Benedikt, Martin, Wallner, Markus, Alber, Hannes, Berger, Rudolf, Lichtenauer, Michael, Saely, Christoph H, Moertl, Deddo, Auersperg, Pia, Reiter, Christian, Rieder, Thomas, Siller-Matula, Jolanta M, Gager, Gloria M, Hasun, Matthias, Weidinger, Franz, Pieber, Thomas R, Zechner, Peter M, Herrmann, Markus, Zirlik, Andreas, Holman, Rury R, Oulhaj, Abderrahim, Sourij, Harald |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622301/ https://www.ncbi.nlm.nih.gov/pubmed/36036746 http://dx.doi.org/10.1093/eurheartj/ehac494 |
Ejemplares similares
-
Timing of SGLT2i initiation after acute myocardial infarction
por: von Lewinski, Dirk, et al.
Publicado: (2023) -
Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction – a post-hoc analysis of the EMMY trial
por: Benedikt, Martin, et al.
Publicado: (2023) -
Alterations in trimethylamine-N-oxide in response to Empagliflozin therapy: a secondary analysis of the EMMY trial
por: Aziz, Faisal, et al.
Publicado: (2023) -
Efficacy and Safety of Intermittent Fasting in People With Insulin-Treated Type 2 Diabetes (INTERFAST-2)—A Randomized Controlled Trial
por: Obermayer, Anna, et al.
Publicado: (2023) -
Simplified Acute Physiology Score 3 Performance in Austrian COVID-19 Patients Admitted to Intensive Care Units with and without Diabetes
por: Aziz, Faisal, et al.
Publicado: (2022)